Skye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up
Skye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.
How this was made
The 30-second read
Why it matters
The transaction is paired with $125M aggregate financings and a stated funding runway into 2029, anchored by RXC008’s planned Phase 2 for fibrostenotic Crohn’s disease.
Market read
Definitive biotech M&A plus a sizable PIPE/financing package is a tradable catalyst, with the main clinical value driver pushed to 2028.
What to watch
Merger completion terms, scheme-of-arrangement conditions, and PIPE dilution details are not provided here, which can drive post-announcement volatility.
Background
Skye and Redx announced a definitive acquisition agreement, with the combined company to operate as Fibrx Therapeutics on Nasdaq.
Ticker impact
Skye Bioscience agreed to acquire Redx via a scheme of arrangement, creating Fibrx Therapeutics and reshaping its clinical pipeline.
Likely supportive for SKYE on deal and financing headlines, with volatility around deal terms and financing execution.
The article discloses a definitive acquisition agreement and aggregate $125M financings intended to fund operations into 2029, which is a direct catalyst for SKYE risk/reward.
Market effects
Biotech fibrosis and GI-focused pipeline assets may see read-across interest as RXC008 is highlighted with Fast Track and Phase 2 planning.
Limited direct regional impact beyond US-listed biotech sentiment.
Financing includes UK-linked British Business Bank participation, but the clinical timeline is US-centric (FDA Fast Track, U.S. IND).
Counterpoint
The long wait to RXC008 Phase 2 topline in 2H 2028 means the deal may not de-risk near-term fundamentals beyond financing and merger mechanics.
Key entities
- companySkye Bioscience, Inc
Acquirer in a definitive transaction agreement to acquire Redx and form Fibrx Therapeutics.
- companyRedx Pharma Ltd.
Target company; its RXC008 program is positioned as the lead asset for the combined entity.
- productRXC008
GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn’s disease, with FDA Fast Track designation and planned Phase 2 topline expected in 2H 2028.
- investorAbingworth
Leads parts of the PIPE and Series A financings supporting the merger.
- investorBritish Business Bank
Participates in the financing package supporting the transaction.
